Age-related macular degeneration is a leading cause of blindness in elder population. In the last decade, intravitreal injection of anti-VEGF agents has shown promising results. Multiple clinical trials have evaluated the safety and efficacy of such agents. In this regard, a human monoclonal antibody, Ranibizumab, has shown improved visual outcomes in elderly patients. This article reviews the outcomes of multiple clinical trials with respect to Ranibizumab’s dosing regimen and new techniques.
Age-related macular degeneration (AMD) is the leading cause of blindness among elderly population (>65 years old) and a major cause of blindness worldwide. The pathogenesis of the disease is the overexpression of vascular endothelial growth factor (VEGF), which causes choroidal neovascularization. This results in leakage of blood and fluid into the macula. However, the introduction of…
